NASDAQ:VCEL
Vericel Corporation Stock News
$47.08
+1.21 (+2.64%)
At Close: May 01, 2024
Vericel Announces Expansion of MACI Coverage by UnitedHealthcare to Include Patella and Multiple Cartilage Defects in the Knee
08:30am, Thursday, 07'th Jan 2021
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that UnitedH
Vericel: Biotech Leader In Engineered Tissue Solutions With Rapid Growth & Profitability
06:48pm, Monday, 04'th Jan 2021
Vericel is a high growth, disruptive biotechnology company with annual sales increasing at a 30% rate prior to the COVID-19 pandemic. The Company's tissue repair and restoration products are proprieta
Post-Covid Outlook for Vericel Is Even Brighter
06:24pm, Monday, 04'th Jan 2021
The company's earnings are expected to increase exponentially in 2021
Vericel to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021
08:30am, Friday, 18'th Dec 2020
CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Co
Vericel: A Rare, High-Quality Small Biotech With Rapid Growth Ahead
06:27am, Friday, 18'th Dec 2020
Vericel is a low-risk, high-quality small biotech with high growth potential. The business is already profitable with 70% gross profit margin and no debt on the balance sheet.
Vericel Corporation (VCEL) CEO Nick Colangelo on Q3 2020 Results - Earnings Call Transcript
09:44pm, Thursday, 05'th Nov 2020
Vericel Corporation (VCEL) CEO Nick Colangelo on Q3 2020 Results - Earnings Call Transcript
Vericel Reports Record Third Quarter Revenues and Net Income
08:00am, Thursday, 05'th Nov 2020
Total Net Revenues of $32.3 Million and Net Income of $3.6 Million
Vericel to Present at Upcoming Investor Conferences
08:30am, Monday, 02'nd Nov 2020
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentation
